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Abstract
Background and purpose
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing, phenotypically heterogeneous
neurodegenerative disease affecting mainly the motor neuron system. The present voxel-
based morphometry (VBM) study investigated whether patterns of brain atrophy differ
among sporadic ALS subtypes.
Material and methods
Sporadic ALS patients (n = 62) with normal cognition and age-matched healthy controls (n =
57) were included in the study. ALS patients were divided into limb- and bulbar-onset groups
according to clinical manifestations at symptom onset (n = 48 and 14, respectively). Clinical
measures were ALS Functional Rating Scale-Revised (ALSFRS-R) score, disease duration,
and forced vital capacity (FVC). Patterns of brain atrophy between ALS subgroups were
compared by VBM.
Results
In limb-onset ALS patients, atrophy was largely confined to the motor cortex and adjacent
pre- and postcentral regions. However, in the bulbar-onset group, affected regions were
more widespread and included these same areas but also extended to the bilateral fronto-
temporal and left superior temporal and supramarginal gyri, and multiple regression analysis
revealed that their ALSFRS-R scores were associated with extensive loss of gray matter
while FVC was related to atrophy in subcortical regions of the left superior temporal gyrus.
In limb-onset ALS patients, disease duration was related to the degree of atrophy in the
motor and adjacent areas.
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Conclusion
Sporadic ALS subtypes show different patterns of brain atrophy. Neural networks related to
limb and bulbar motor functions in each ALS subtype may underlie their distinct patterns of
cerebral atrophy. That is, more extensive cortical and subcortical atrophy is correlated with
greater ALSFRS-R severity and shorter disease duration in the bulbar-onset subtype and
may explain the poor prognosis of these patients.
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal and rapidly progressing neurodegenerative dis-
ease affecting both upper and lower motor neuron systems [1]. Despite the elucidation of
genetic and molecular mechanisms of motor neuron cell death in ALS, the selectivity of
affected motor neuron areas is not well understood and there are no effective therapeutic
agents available for treatment [2]. The recent identification of novel genes linking ALS with
frontotemproral dementia and the emerging concept of multisystem proteinopathies have
changed the widely held belief that ALS affects only the motor neuron system [3, 4]. In addi-
tion, ALS patients manifesting only motor symptoms typically show heterogeneous clinical
progression, and their prognosis can be predicted by the initial clinical presentation of either
limb or bulbar onset, a reduced score on the revised Amyotrophic Lateral Sclerosis Functional
Rating Scale (ALSFRS-R), and decreased forced vital capacity (FVC) [5].
Our recent data has demonstrated that diverse frontal dysfunction occurs in about 50% of
sporadic ALS patients who harbor no known mutations in causative genes such as C9ORF72,
SOD1, FUS, and TDP43 [3, 6]. We also found that cognitive impairment was negatively corre-
lated with patient prognosis and survival [7]. Based on these findings, the present study investi-
gated whether ALS subtypes with normal cognition but with distinct clinical presentation
show differences in terms of changes in brain structure. We evaluated differences in regional
brain volumes between limb- and bulbar-onset ALS patients to test the hypothesis that differ-
ent patterns of brain atrophy are associated with clinical measures including ALSFRS-R score,
disease duration, and FVC.
Materials and Methods
Subjects
A total of 319 sporadic ALS patients were recruited between 2008 and 2012 for this study who
met the criteria for clinically definite or probable (laboratory-supported) ALS [8]; of these, 96
were excluded due to systemic medical disease (n = 3), psychiatric illness or use of psychiatric
drugs (n = 9), other neurological disease (e.g., stroke, trauma, or learning disability) (n = 16),
or insufficient neuropsychological testing (n = 68). Based on neuropsychological test results
and magnetic resonance imaging (MRI) data, 103 ALS patients who showed abnormal cogni-
tive findings based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edi-
tion criteria [9] were evaluated on most tasks in the Seoul Neuropsychological Screening
Battery [7, 10]. An additional 58 patients from the remaining 120 who were cognitively normal
[7] were also excluded based on the following criteria: age over 75 years; simultaneous presen-
tation of limb motor signs and bulbar symptoms; and history of respiratory support (tracheos-
tomy, non-invasive ventilation, or oxygen inhalation). Ultimately, 62 sporadic ALS patients
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with limb (n = 48) or bulbar (n = 14) onset with analyzable MRI data were included in the
study (S1 Fig).
We analyzed clinical features of the disease. Onset symptoms were collected by experienced
medical staff through interviews with patients or their family members. ALS subgroups were
classified based on initial clinical presentation, as follows: limb onset cases were defined as hav-
ing limb motor symptoms or signs (weakness or atrophy or fasciculation) and no bulbar signs
or symptoms at the time point of initial manifestations. Bulbar onset cases were defined as hav-
ing only bulbar signs or symptoms including dysarthria, swallowing difficulty and tongue fas-
ciculation and no limb weakness.
The control group consisted of 57 sex- and age-matched healthy subjects. We obtained
written informed consent to participate and enrollment of cohort. The ethics committees/IRBs
approved this consent procedure. The study protocol was approved by the Institutional Review
Board of Hanyang University Hospital, Seoul, South Korea (HYU 2010-04-011).
Clinical measurements
ALSFRS-R is used to evaluate the functional status of ALS patients [11] based on 12 items,
including: bulbar symptoms, limb/axial muscle function, and respiratory symptoms, each of
which are rated on a scale of 0–4. Total functional disability scores range from 0 (maximum
disability) to 48 (normal) points. Patients’ respiratory function was estimated by FVC (% of
predicted normal value) using a conventional pulmonary function test [12]. Disease duration
was defined as the time interval from initial symptom onset to the time of MRI, at which time
other clinical parameters were also measured.
Image acquisition
MRI was carried out using a 3.0-T Achieva system (Phillips, Best, The Netherlands) equipped
with a standard quadrature head coil. Structural MRI sequences were obtained as a volumetric
three-dimensional spoiled fast gradient echo with the following parameters: repetition time =
7.3 ms; echo time = 2.7 ms; slice thickness = 1.0 mm; flip angle = 13˚; and field of view =
256 × 256 mm. The volume consisted of 200 contiguous coronal sections covering the entire
brain.
VBM analysis
VBM is a fully automated, whole-brain technique that enables measurement of regional brain
volumes based on voxel-wise comparison of gray and white matter volumes using Statistical
Parametric Mapping 12 software (SPM12; Functional Imaging Laboratory, Wellcome Depart-
ment of Imaging Neuroscience, Institute of Neurology, London, UK; http://www.fil.ion.ucl.ac.
uk/spm) running on Matlab 2015b (Matworks, Natick, MA, USA). Structural images were
bias-corrected, tissue-classified, and normalized to a standard template using high-dimen-
sional DARTEL normalization. Images were segmented into gray, white, and cerebrospinal
fluid compartments using VBM8 preprocessing in SPM12. The ‘check data quality’ function
was used to verify segmentation results. Gray and white matter volumes were smoothed using
a 12-mm full width at half-maximum Gaussian filter.
Statistical analysis
Differences in demographic factors and clinical parameters of each ALS subtype were evalu-
ated with the t test for independent samples for continuous variables and with the χ2 test for
categorical variables with Bonferroni correction in the post-hoc analysis. Data are presented as
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median values with standard deviation and ranges. The normality of data distributions was
tested with the Kolmogorov–Smirnov test. P values< 0.05 were considered statistically signifi-
cant. Statistical analyses were performed using SPSS v.22 software (SPSS Inc., Chicago, IL.
USA). MR data were analyzed with the two-sample t test to compare regional volumes between
ALS patients and controls. Group differences between bulbar- and limb-onset ALS were
assessed using SPM 12. Age, sex, and total intracranial volume were corrected for as confound-
ing variables in an analysis of covariance. Specifically, single linear regression analyses with
clinical parameters were performed in limb- and bulbar-onset ALS for the following contrasts:
ALSFRS-R composite score, disease duration, and FVC (%). We accepted a statistical threshold
of P< 0.001 (uncorrected) with an extent threshold of 100 voxels and P< 0.05 (corrected)
using family-wise error methods [13].
Results
Clinical characteristics of the study population
Limb- and bulbar-onset ALS groups did not differ in terms of demographic factors including
sex and age or clinical parameters including ALSFRS-R score and FVC. Disease progression—
which was estimated from the decline in ALSFRS-R score from the time of symptom onset
determined by MRI (48-ALSFRS-R at MRI/disease duration in months)—showed more rapid
progression in the bulbar-onset subtype, although the difference was not significant. However,
disease duration was significantly shorter in this group as compared to limb-onset ALS
patients (15.64 ± 8.12 vs. 26.17 ± 19.12, P < 0.05) (Table 1).
Patterns of brain atrophy in gray and white matter
We compared regions exhibiting gray and white matter atrophy in ALS patients and controls.
In the former, we observed reduced gray matter density in the bilateral frontal cortex (espe-
cially the middle frontal gyrus and right precentral and postcentral gyrus), cerebellum, left
superior temporal gyrus, left inferior parietal gyrus, and insula (S1 Table and S2A Fig). Analy-
sis of white matter revealed that the right paracentral lobule, right insula, right Rolandic oper-
culum, and right superior temporal, left postcentral, and left superior frontal gyri were
markedly atrophied in ALS patients relative to controls (S1 Table and S2B Fig).
Table 1. Demographic and clinical characteristics of ALS patients and control subjects.
ALS Limb-onset ALS Bulbar-onset ALS Control
Characteristics
Number of subjects with probable or definite ALS 62 (56/6) 48 (46/2) 14 (10/4) 57
Sex (male/female)* 33/29 29/19 4/10 20/23
Age (years)* 52.73 ± 10.05 50.95 ± 11.10 56.78 ± 7.16 51.09 ± 5.17
ALSFRS-R score* 37.31 ± 6.46 37.23 ± 6.08 37.50 ± 7.44 N/A
Months from ALS disease onset* 28.07 ± 18.99 26.17 ± 19.12† 15.64 ± 8.12† N/A
Disease progression*‡ 0.58 ± 0.45 0.53 ± 0.38 0.74 ± 0.64 N/A
FVC* 61.27 ± 25.03 64.35 ± 25.22 52.78 ± 23.64 N/A
* Values represent mean sent.
†P = 0.05 (=2 test with post hoc Bonferroni correction).
‡ Progression rate was estimated from the decline in ALSFRS-R score after symptom onset (48-ALSFRS-R at MRI/disease duration).
ALS, amyotrophic lateral sclerosis; ALSFRS-R, Korean version of ALS Functional Rating Scale—Revised; FVC, forced vital capacity.
doi:10.1371/journal.pone.0168424.t001
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Differences in brain atrophy between and within limb- and bulbar-onset
ALS subtypes
We separately compared atrophy patterns in the limb- and bulbar-onset ALS subtypes to that
of controls. Limb-onset ALS patients showed more gray matter atrophy in bilateral supple-
mentary motor areas (SMA) and inferior frontal and superior temporal areas relative to con-
trols (Fig 1A and S2 Table), whereas the bulbar-onset subtype showed SMA and inferior
frontal area atrophy, but exhibited more extensive atrophy than the limb-onset group (Fig 1C
and S2 Table).
Compared to controls, limb-onset ALS patients showed white matter atrophy in motor and
adjacent areas. In contrast, the bulbar-onset group showed more widespread involvement of
white matter tracts, including motor and extra-motor regions (Fig 1B, 1D and S3 Table). Atro-
phic changes in the bulbar onset subtype were more widespread than in limb-onset patients,
extending to extra-motor regions including SMA, superior frontal, inferior temporal, and cer-
ebellar areas (Fig 2A and 2C). Similarly, white matter atrophy was limited to the left middle
temporal regions in limb-onset ALS, whereas bulbar-onset patients showed multiple affected
areas in the frontotemporal region and bilateral cerebellum (Fig 2B and 2D). Comparative
data on the patterns of brain atrophy in each ALS subtype are summarized in Table 2.
Relationship between clinical parameters and atrophic patterns in limb-
vs. bulbar-onset ALS
ALSFRS-R score was associated with atrophy in multifocal gray matter areas including the
bilateral frontal, left superior, and supramarginal gyri in bulbar-onset patients. However, limb-
onset patients showed atrophy in the left orbitofrontal area (Fig 3A and 3C); in this group but
not the bulbar-onset group, atrophy in the motor and left frontal areas was related to disease
duration (S2C and S2D Fig). In the latter patients, focal atrophy in the subcortex of the left
superior temporal gyrus was associated with FVC (S2E and S2F Fig) whereas in the former,
FVC was unrelated to changes in gray and white matter volume.
Discussion
Recent evidence suggests that ALS is a multisystem neurodegenerative disease involving both
sensory and extrapyramidal systems [14]. Over 50% of ALS cases show cognitive impairment
involving many components of the central nervous system [15, 16]. Neuroimaging studies can
provide insight into the relationship between anatomical and functional abnormalities in
motor and neural networks that depend on afferent and efferent connections [14]. Our imag-
ing study evaluating changes in gray and white matter in sporadic ALS patients with normal
cognitive function and only pure motor manifestations can clarify the clinical correlates. To
this end, the current study examined differences in atrophy between limb- and bulbar-onset
ALS and the associated clinical changes. Widespread cortical and subcortical atrophy in the
motor and adjacent regions as well as extra-motor regions were observed in ALS patients. Fur-
thermore, the bulbar-onset subtype showed multifocal and more extensive atrophy in extra-
motor gray and white matter than limb-type ALS. These findings suggest that atrophy occurs
at the initial anatomical site linked to progressive motor deterioration.
We found the ALSFRS-R score was highly correlated with the severity of gray and white
matter atrophy in bulbar-onset ALS. Others have reported that clinical progression in this sub-
type is more rapid than in limb-onset ALS based on ALSFRS-R score [17]. We observed a simi-
lar trend; this may be explained by more extensive atrophy in multifocal, extra-motor gray
matter areas, including bilateral frontal lobes and the left supramarginal gyrus as well as motor
Regional Differences of the Brain According to Clinical Profile of ALS
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Fig 1. Regional atrophy in ALS patients relative to controls. (A, C) Limb-onset ALS showing gray matter atrophy in bilateral inferior frontal, left
superior frontal, and left precentral gyri, SMA, and thalamus (A). In bulbar-onset ALS, atrophy was detected in bilateral frontal lobes, left superior
temporal pole, and left inferior parietal, precentral, and postcentral gyri relative to healthy controls (C). In limb-onset ALS, white matter atrophy
occurred around motor and association areas (SMA and around central lobules). (B, D) In the bulbar type, multiple areas of the white matter tract in
extra-motor areas (SMA and inferior and superior frontal gyri) as well as the motor area were affected (displayed at P < 0.001, uncorrected, extended
threshold = 100 voxels). The colored bar represents the T score.
doi:10.1371/journal.pone.0168424.g001
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Fig 2. Comparative analysis of regional gray and white matter atrophy between limb- and bulbar-onset ALS patients. (A, B) The limb-
onset subtype was characterized by decreased gray matter volume around motor areas (pre- and post-central and medial superior frontal areas)
relative to the bulbar-onset subtype. (C, D) The bulbar-onset subtype exhibited atrophy in both gray and white matter in extra-motor areas—i.e.,
bilateral frontal, temporal, and cerebellar areas as compared to the limb type (displayed at P < 0.001, uncorrected, extended threshold = 100
voxels). The colored bar represents the T score.
doi:10.1371/journal.pone.0168424.g002
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regions. In contrast, in limb-onset ALS patients, only left orbitofrontal atrophy was associated
with ALSFRS-R. These results suggest that the patterns and extent of brain atrophy in our
study may be useful for predicting the progression of ALS.
Motor-related regional atrophy (e.g., in the SMA) was found to be independent of onset
type. We also found that bulbar-onset patients exhibited atrophy in the bilateral frontotem-
poral lobes irrespective of disease duration. In contrast, in the limb-onset subtype, atrophy was
confined to the precentral cortex and adjacent regions—that is, to anatomical regions related
to motor control [5]. In bulbar-onset patients, more extensive anatomical changes may pre-
cede bulbar manifestations even at an early stage. Our findings may be related to prior obser-
vations of poor prognosis in this ALS subtype [18–22]. Interestingly, despite the shorter
disease duration in these patients, gray and white matter atrophy was more widespread than in
those with limb-onset ALS corresponding to their poor prognosis [21], [22]. One report
described the importance of the corpus callosum in bulbar ALS as a predictor of poor progno-
sis [23]; however, we found no evidence of corpus callosum involvement in this study, which
may due to the heterogeneity of ALS patients [24] and different selection criteria that were
used for patient recruitment—for instance, the inclusion of only cognitively normal ALS
patients in the present study.
FVC is an another useful parameter for predicting ALS patient prognosis [19, 20]. In con-
trast to a previous report [25], there was no evidence of a relationship between respiratory
function and brain atrophy, except for the observation that the left superior temporal subcor-
tex is involved in bulbar-onset ALS. The mean FVC of patients enrolled in this study was more
than 60% of the predicted normal value and most patients did not present severe respiratory
Table 2. Summary of atrophied regions in limb- vs. bulbar-onset ALS.
Atrophied areas* Limb-onset ALS Bulbar-onset ALS
Gray matter Compared controls SMA (B) SMA (B)
Medial orbitofrontal (L) Precentral (L)
Medial superior frontal (L) Superior frontal (L)
Inferior parietal (L) Inferior frontal, orbitalis (B)
Superior temporal pole (L) Thalamus (B)
Insular (L)
Comparison within ALS subgroups Precentral (B) SMA (R)
Postcentral (B) Superior frontal (B)
Medial superior frontal (B) Inferior temporal (L)
Cerebellum (B)
White matter Compared controls SMA (L) SMA (B)
Precentral (R) Precentral (R)
Paracentral lobule (L) Postcentral (L)
Superior temporal (L) Superior frontal (R)
Heschl’s gyrus (L) Middle frontal (B)
Insula (B) Medial superior frontal (R)
Cerebellum vermis Cerebellum (L)
Comparison within ALS subgroups Middle temporal (L) Superior frontal (B)
Middle temporal (R)
Inferior temporal (L)
Cerebellum (B)
*All atrophied areas were based on AAL regions.
ALS, amyotrophic lateral sclerosis; B, bilateral; L, left; R, right; SMA, supplementary motor area.
doi:10.1371/journal.pone.0168424.t002
Regional Differences of the Brain According to Clinical Profile of ALS
PLOS ONE | DOI:10.1371/journal.pone.0168424 January 17, 2017 8 / 14
Fig 3. Different atrophic patterns in bulbar- and limb-onset ALS patients according to ALSFRS-R scores. (A, B) The bulbar-onset group showed
atrophy in the bilateral frontal, left superior temporal, and supramarginal gyri (A). The limb-onset group showed atrophy in the left orbitofrontal area (B)
(displayed at P < 0.001, uncorrected, extended threshold 100 voxels). The colored bar represents the T score.
doi:10.1371/journal.pone.0168424.g003
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insufficiency; moreover, there was no difference in FVC between the two ALS subtypes, which
may be explain why respiratory symptoms were not correlated with brain atrophy. Another
plausible explanation is that the link between respiratory function and ALS prognosis is related
to weakness of respiratory muscles rather than to cortical or subcortical changes.
A previous study reported cortical thinning around primary motor areas in patients with
spinal- but not bulbar-onset ALS as compared to healthy controls [26]. Another group found
that the site of disease onset (bulbar/lower limb) showed the most pronounced thinning in the
corresponding area of the motor cortex, specifically in the region harboring upper motor neu-
rons [27]. Although brain volume differed between limb- and bulbar-onset subtypes of ALS,
they showed similar total gray or white matter volumes [28]. ALS patients exhibit localized
bilateral deficits in gray matter volume centered in Brodmann’s areas 8, 9, and 10 along with
bilateral reductions in white matter volume from the precentral gyrus to the internal capsule
and brainstem relative to healthy control subjects, consistent with the course of the corticosp-
inal tract. In contrast, there was no loss in gray matter volume in the precentral gyrus [28].
VBM is relatively sensitive to extra-motor—especially frontotemporal cerebral—changes [29].
Although multimodal MRI studies of ALS patients can be used to characterize disease-specific
pathology, they are limited by inconsistent results due to small sample size, suboptimal patient
characterization, lack of post-mortem validation of imaging findings, heterogeneity of disease
progression, and a paucity of longitudinal data [30, 31]. Previous VBM analyses of ALS have
yielded inconsistent findings [14], possibly due to diverse factors such as covariates [32],
matching, sampling severity, sample size [33], template normalization [34], threshold masking
[35], imaging protocols [36], and statistical modeling [37]. Although volumetric imaging and
similar approaches cannot recapitulate neuropathological findings of the central nervous sys-
tem, the recent development of image acquisition and analytical tools has provided new
insights into neural networks involved in ALS [14] as well as evidence of extra-motor involve-
ment [14, 38–42]. According to recent meta-analysis data based on analysis of 116 studies
reported that the MRI biomarkers appear to be well correlated with disease severity, duration
and progression and are more sensitive not only in the spinal cord motor regions but also
more extensive brain regions [43]. This study suggest that VBM could be one of reliable image
biomarkers to predict prognosis and reveal clinically silent involvement of ALS, even though
there are some limitations such as the clinical various phenotypes and the lack of large and lon-
gitudinal studies [43].
This study had some limitations. Firstly, there was a large discrepancy between the two clin-
ical groups even though it was a prospective cohort study. Secondly, observations on white
matter lesions must be interpreted with caution. Diffusion tensor imaging (DTI) is a more use-
ful tool than VBM for detecting network degeneration in ALS and evaluating network integrity
than selected measurements of grey or white matter [30, 43–45]. There is a need for large
cohorts with long term DTI and clinical follow-up for solving this issue. Thirdly, we attempted
to obtain more reliable results for the FWE correction. However, we failed to obtain positive
results under FWE correction, even though there were positive finds in the uncorrected analy-
ses (p<0.001). Studies with larger sample size will typically be able to apply the harsh FWE cor-
rection for multiple comparisons, however, it may be difficult to obtain positive findings in a
study with a small sample size [13, 46]. Many other researchers have reported image results of
ALS using an uncorrected p value [46, 47]. There is possibility of over-interpretation in poten-
tially false positives observed significant uncorrected results in this study.
In summary, this study found that sporadic ALS patients with normal levels of cognition
and pure motor symptoms show multiple sites of cortical and subcortical atrophy in areas that
extend beyond motor regions. This was especially apparent in bulbar-onset patients, suggest-
ing that neural network dysfunction—particularly salient and central executive networks such
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as insular and fronto-orbital cortical and associated subcortical regions—underlies ALS, with
the different subtypes showing distinct atrophic patterns. Given that ALS involves focal degen-
eration that spreads to through upper and lower motor levels [48], it is assumed that bulbar-
onset patients experience more rapid and contiguous spreading of brain atrophy. Therefore,
VBM analysis of gray and white matter atrophy in ALS can provide a basis for predicting ALS
progression and prognosis.
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S1 Fig. Selection of study participants. A total of 319 clinically probable laboratory-supported
ALS patients were enrolled in the study. Neuropsychological testing was carried out on 223
patients; 120 showed normal cognitive function, and 62 underwent neuroimaging for VBM
analysis. The control group consisted of 57 age-matched subjects.
(TIF)
S2 Fig. (A, B) Patterns of atrophy in ALS patients relative to healthy controls. (C, D) Atro-
phied regions included motor and extramotor areas of gray and white matter. Different pat-
terns were observed in bulbar- and limb-onset ALS patients according to disease duration.
Patients with limb-onset disease showed atrophy in the left frontal and motor subcortical areas
within the primary motor region. (E, F) Decreased FVC was correlated with atrophy in bilat-
eral superior temporal and orbitofrontal subcortical areas in the bulbar-onset subtype (dis-
played at P< 0.001, uncorrected, extended threshold = 100 voxels). The colored bar
represents the T score.
(TIF)
S1 Table. Relative decrease in brain volume in all ALS patients compared to controls.
There was reduced gray matter density in the bilateral frontal cortex, cerebellum, left superior
temporal gyrus, left inferior parietal gyrus, and insula in ALS.
(DOCX)
S2 Table. Relative decrease in gray matter volume of bulbar and limb-onset ALS compared
to controls. There were more gray matter atrophy in bilateral supplementary motor areas
(SMA) and inferior frontal and superior temporal areas relative to controls in limb-onset ALS
patients, whereas the bulbar-onset subtype showed SMA and inferior frontal area atrophy, but
exhibited more extensive atrophy than the limb group.
(DOCX)
S3 Table. Relative decrease in white matter volume of bulbar- and limb-onset ALS patients
compared to controls. Limb-onset ALS patients showed white matter atrophy in motor and
adjacent areas. In contrast, the bulbar-onset group showed more widespread involvement of
white matter tracts, including motor and extra-motor regions.
(DOCX)
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